MedPath

Repercussions of electrostimulation in women with breast cancer during chemotherapy

Not Applicable
Not yet recruiting
Conditions
malignant neoplasm of the breast
pharmacological treatment
nausea
vomit
Q65.020
C23.888.821.712
C23.888.821.937
Registration Number
RBR-4ccv6f
Lead Sponsor
universidade federal de santa maria
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not yet recruiting
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Women with indications of chemotherapy neoadjuvant or adjuvant, of high and moderate emetogenic potential; age between 35 and 75 years

Exclusion Criteria

Central nervous system metastasis;second chemotherapy treatment

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction of nausea and vomiting during chemotherapy verified through the Edmonton and MASCC Antiemesis Tool questionnaires, from a significant variation of 35% intensity and 36% in the frequency of nausea and 30% in the frequency of vomiting.<br><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath